SAN DIEGO, Sept. 30, 2010 (GLOBE NEWSWIRE) -- Bio-Matrix Scientific Group Inc. (OTCBB:BMSN) Chairman & CEO David Koos commented today about the future of stem cell therapy and how advances in regenerative medicine will fuel demand for stem cell repositories.
David Koos, the Company's Chairman & CEO, stated, "As stem cell therapies are developed for treating maladies that have yet to be successfully addressed by traditional methods, patients and doctors will become more reliant on stem cells readily available for use. Our company believes this future need for stem cells will result in a widespread increase in stem cell banking and that demand for banking of bone marrow, endometrial and adipose (fat) derived stem cells will exceed the demand for cord blood banking. The Company's goal is to be able to play a key role in fulfilling that demand."
A spokesperson for the company noted that Bio-Matrix Scientific Group is currently identifying potential partners to participate with the company in developing adult stem cell repositories in various geographical locations.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB:BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos also serves as Chairman & CEO for the company's majority owned subsidiary, Entest BioMedical, Inc. (OTCBB:ENTB).
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT: Bio-Matrix Scientific Group Inc. David R. Koos, Chairman & CEO 619.702.1404 Fax: 619.330.2328 www.BMSN.us info@BMSN.us